Breast Cancer Clinical Trial
Official title:
Comparison Between the Effects of Intravenous Morphine, Tramadol and Ketorolac on Stress and Immune Responses in Patients Undergoing Modified Radical Mastectomy
Comparison between the effects of intravenous morphine, tramadol and ketorolac on stress and immune responses in patients undergoing modified radical mastectomy
Sixty patients aged (20-60 years), weighting (50 -75 Kg), with American Society of
Anesthesiologists (ASA) physical status I or II scheduled for modified radical mastectomy
surgery under general anesthesia were enrolled in this prospective clinical study. The
Ethics Committee of South Egypt Cancer Institute (SECI), assuit University, assuit, Egypt
approved the study. Informed written consent was obtained from each patient to be enrolled
in this study.
Patients with known allergy to opioids or Non Steroidal Anti-inflammatory drugs NSAIDs, with
gastric or duodenal ulcer, on radiotherapy or chemotherapy, received blood transfusion
before the surgery or preoperative NSAIDs, steroid or opioid medications 48 hours prior to
operation were excluded.
All patients were taught how to evaluate their own pain intensity using the visual analogue
scale (VAS) scored from 0 to 10 (where 0 = no pain and 10 = the worst pain imaginable). Both
the patient and the anesthetist involved in the study were kept blinded to group assignment.
Randomization codes were not decoded till the end.
No pre-medications were given. Basic monitoring probes (ECG, non invasive blood pressure,
end-tidal carbon dioxide, pulse oximetry and temperature) were applied. base line VAS,
sedation score, systolic and diastolic blood pressure, heart rate, respiratory rate and
oxygen saturation were assessed before the beginning of surgery. Venous blood sample was
taken for assessment of the base line stress hormones (cortisol, prolactin) and immune
response (cluster of differentiation (CD) 3, 4, 8 and 56), General anesthesia was induced
with I.V. fentanyl 1 μg/kg, thiopental 5mg/kg. Endotracheal intubation was facilitated by
cis-atracurium 0.15 mg/kg, and was maintained with isoflurane 1.5-1.7 MAC, cis-atracurium
0.03 mg/kg and controlled ventilation in a ventilation parameters that maintain normocapnia
(35- 45 mmHg). Neuromuscular block was antagonized by neostigmine 50µg/kg and atropine
20µg/kg. Venous blood sample was taken for assessment of stress hormones (cortisol,
prolactin) and immune response (CD3, CD4, CD8 and CD56) immediately postoperatively after
extubation in the operative room before the analgesic drug administration. VAS, sedation
score, systolic and diastolic blood pressure, heart rate, respiratory rate and oxygen
saturation were also assessed. Patients were allocated according to computer-generated
randomization tables into one of three groups of 20 patients each to receive:
Group I: (n=20) received IV 0.1mg/kg morphine sulphate (morphine sulfate ®, Misr CO Pharma).
Group II: (n=20) received IV 2 mg/kg tramadol Hcl (tramadol ®, October Pharma S.A.E).
Group III: (n=20) received IV 30 mg ketorolac tromethamine (ketorolac ®, Amriya Pharma).
Patients were transferred to the post anesthesia care unit (PACU). During this period
observation of heart rate, systolic and, diastolic blood pressure, respiratory rate, oxygen
saturation and VAS were recorded at 2, 4, 6, 8, 12, 18 and 24hrs postoperatively. In
addition, side effect such as nausea, vomiting, respiratory depression and sedation (using
sedation score from 0 to 4, where 0= awake, 1= easily aroused, 2= awaken after verbal
stimulation, 3=awaken after tactile stimulation and 4= not arousable) were recorded and
treated. Another venous blood samples were taken for assessment of stress hormones at 40
mins, immune response at 90 mins and for both stress hormones and immune responses at 24
hours later. In order to keep VAS ≤ 3 for 24hours postoperative, repeated doses of the same
analgesic medications (morphine to the first group, tramadol to the second group, and
ketorolac to the third group) were given all over the observation period at the same doses.
Determination of serum cortisol and prolactin levels was done by fully automated ELISA
(enzyme linked immunosorbent assay) (EVOLIS®, Biorad, Germany). Expressions of (CD3+, CD4+,
CD8+ and CD56+) in blood samples were measured as percentages of total lymphocytes by
fluorescence activated cell sorter (FACS) calibur flow cytometry with cell quest software
(Becton Dickinson Biosciences, USA). Anti-human IgG was used as an iso type-matched negative
control for each sample. Forward and side scatter histogram was used to define the
lymphocyte population. Then, the percentages of CD3+, CD4+, CD8+ and CD56 were assessed in
lymphocytes population. The positive percentage was >20%
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |